Initial testing of aplidin by the pediatric pre-clinical testing program.
Publication
, Journal Article
Morton, CL; Houghton, PJ; Gorlick, R; Kolb, EA; Lock, R; Carol, H; Keir, ST; Reynolds, CP; Kang, MH; Maris, JM; Billups, C; Smith, MA
Published in: Pediatr Blood Cancer
September 2009
Aplidin was tested in vitro at concentrations ranging from from 0.1 nM to 1.0 microM and in vivo at a dose of 0.6 mg/kg administered intraperitoneally on an every 4 days x 3-schedule that was repeated at day 21. In vitro, Aplidin was most active against acute lymphoblastic leukemia (ALL) cell lines. In vivo, Aplidin induced significant differences in EFS distribution in 12 of 28 (43%) solid tumor models and 2 of 6 evaluable ALL models. Aplidin showed potent in vitro activity and induced significant in vivo tumor growth inhibition in some xenografts, but did not induce tumor regressions.
Duke Scholars
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
September 2009
Volume
53
Issue
3
Start / End Page
509 / 512
Location
United States
Related Subject Headings
- Xenograft Model Antitumor Assays
- Peptides, Cyclic
- Oncology & Carcinogenesis
- Mice, SCID
- Mice, Inbred BALB C
- Mice
- Humans
- Female
- Depsipeptides
- Cell Line, Tumor
Citation
APA
Chicago
ICMJE
MLA
NLM
Morton, C. L., Houghton, P. J., Gorlick, R., Kolb, E. A., Lock, R., Carol, H., … Smith, M. A. (2009). Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer, 53(3), 509–512. https://doi.org/10.1002/pbc.21976
Morton, Christopher L., Peter J. Houghton, Richard Gorlick, E Anders Kolb, Richard Lock, Hernan Carol, Stephen T. Keir, et al. “Initial testing of aplidin by the pediatric pre-clinical testing program.” Pediatr Blood Cancer 53, no. 3 (September 2009): 509–12. https://doi.org/10.1002/pbc.21976.
Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, et al. Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer. 2009 Sep;53(3):509–12.
Morton, Christopher L., et al. “Initial testing of aplidin by the pediatric pre-clinical testing program.” Pediatr Blood Cancer, vol. 53, no. 3, Sept. 2009, pp. 509–12. Pubmed, doi:10.1002/pbc.21976.
Morton CL, Houghton PJ, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA. Initial testing of aplidin by the pediatric pre-clinical testing program. Pediatr Blood Cancer. 2009 Sep;53(3):509–512.
Published In
Pediatr Blood Cancer
DOI
EISSN
1545-5017
Publication Date
September 2009
Volume
53
Issue
3
Start / End Page
509 / 512
Location
United States
Related Subject Headings
- Xenograft Model Antitumor Assays
- Peptides, Cyclic
- Oncology & Carcinogenesis
- Mice, SCID
- Mice, Inbred BALB C
- Mice
- Humans
- Female
- Depsipeptides
- Cell Line, Tumor